Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03892889 · ClinicalTrials.gov registry record · Phase 3
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Terminated
- Registry status
- Phase 3
- Development phase
- 277
- Enrollment target
NCT03892889 is a Phase 3 study that was terminated before completion, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 277 participants.
The verdict
NCT03892889, a Phase 3 study, was terminated before completion, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 277 participants
- Enrollment target
Study Summary
To compare inpatient psychiatric hospitalization rates while participants are on oral standard-of-care antipsychotic treatment and later switched to Abilify MyCite®.
Interventions
- COMBINATION_PRODUCT Abilify MyCite®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2020-09-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03892889
The ClinicalTrials.gov registry entry for NCT03892889 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abilify MyCite® is the first listed.
NCT03892889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03892889 about?
NCT03892889 is a clinical study titled "A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®". To compare inpatient psychiatric hospitalization rates while participants are on oral standard-of-care antipsychotic treatment and later switched to Abilify MyCite®.
What is the current status of trial NCT03892889?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 277 participants. The study started on 2019-04-29. Estimated completion is 2020-09-29.
What interventions are being tested in trial NCT03892889?
The interventions under investigation include: Abilify MyCite® (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03892889?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.